HK1219758A1 - 通過自然反義轉錄物對去乙酰化酶 的抑制達到對去乙酰化酶 相關疾病的治療 - Google Patents

通過自然反義轉錄物對去乙酰化酶 的抑制達到對去乙酰化酶 相關疾病的治療

Info

Publication number
HK1219758A1
HK1219758A1 HK16107821.2A HK16107821A HK1219758A1 HK 1219758 A1 HK1219758 A1 HK 1219758A1 HK 16107821 A HK16107821 A HK 16107821A HK 1219758 A1 HK1219758 A1 HK 1219758A1
Authority
HK
Hong Kong
Prior art keywords
sirt
sirtuin
inhibition
treatment
related diseases
Prior art date
Application number
HK16107821.2A
Other languages
English (en)
Inventor
Joseph Collard
Sherman Olga Khorkova
Original Assignee
Curna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/066445 external-priority patent/WO2010065662A2/en
Priority claimed from PCT/US2010/026119 external-priority patent/WO2010102058A2/en
Application filed by Curna Inc filed Critical Curna Inc
Publication of HK1219758A1 publication Critical patent/HK1219758A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16107821.2A 2009-07-24 2016-07-05 通過自然反義轉錄物對去乙酰化酶 的抑制達到對去乙酰化酶 相關疾病的治療 HK1219758A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22839209P 2009-07-24 2009-07-24
US25907209P 2009-11-06 2009-11-06
PCT/US2009/066445 WO2010065662A2 (en) 2008-12-04 2009-12-02 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
PCT/US2010/026119 WO2010102058A2 (en) 2009-03-04 2010-03-03 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
US33042710P 2010-05-03 2010-05-03

Publications (1)

Publication Number Publication Date
HK1219758A1 true HK1219758A1 (zh) 2017-04-13

Family

ID=46124982

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107821.2A HK1219758A1 (zh) 2009-07-24 2016-07-05 通過自然反義轉錄物對去乙酰化酶 的抑制達到對去乙酰化酶 相關疾病的治療

Country Status (3)

Country Link
EP (2) EP2467481A4 (zh)
ES (1) ES2854004T3 (zh)
HK (1) HK1219758A1 (zh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087093A (en) * 1996-01-26 2000-07-11 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
WO2005090996A1 (en) * 2004-03-15 2005-09-29 Regeneron Pharmaceuticals, Inc. Sirt6 transgenic non-human animals and assay methods
US8193332B2 (en) * 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2005110464A2 (en) * 2004-05-14 2005-11-24 Oregon Health & Science University Irx5 inhibition as treatment for hyperproliferative disorders
WO2006006171A2 (en) * 2004-07-14 2006-01-19 Gamida-Cell Ltd. Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the sir2 family of enzymes
WO2006069592A2 (en) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Method for diagnosing an/or predicting preeclampsia and/or related disorders
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
JP2008195673A (ja) * 2007-02-14 2008-08-28 Nippon Meat Packers Inc 延命効果物質、および感染防御効果・ワクチン効果促進物質、前記物質の検定用コンストラクト、並びにそれらの用途
WO2009140562A1 (en) * 2008-05-15 2009-11-19 Sirtris Pharmaceuticals, Inc. Sirt1 polymorphic variants and methods of use thereof
CN108042560A (zh) * 2008-12-04 2018-05-18 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病

Also Published As

Publication number Publication date
EP2467481A4 (en) 2013-01-16
EP2985348A3 (en) 2016-04-20
EP2985348B1 (en) 2020-12-30
EP2985348A2 (en) 2016-02-17
EP2467481A2 (en) 2012-06-27
ES2854004T3 (es) 2021-09-20

Similar Documents

Publication Publication Date Title
HK1217031A1 (zh) 通過抑制 的天然的反義轉錄物來對 相關疾病所進行的治療
HK1217729A1 (zh) 通過對天然反義轉錄到 的抑制治療組蛋白去乙酰化酶 相關疾病
EP2427552A4 (en) TREATMENT OF TRISTETRAPROLIN (TTP) -REVATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST TTP
EP2352830A4 (en) TREATMENT OF APOLIPOPROTEIN A1-RELATED DISEASES BY INHIBITION OF A NATURAL ANTISENSE TRANSCRIPTION PRODUCT OF APOLIPOPROTEIN A1
EP2370580A4 (en) TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRTUIN 1
EP2427554A4 (en) TREATMENT OF DYSTROPHINE-CONTAINING ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST THE DMD FAMILY
EP2443237A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH COLLAGEN TREATMENT BY INHIBITION OF THE NATURAL ANTISENSE TRANS- SCRIPTS TO A COLLAGEN
EP2432881A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH REPROGRAMMING FACTORS BY INHIBITION OF THE NATURAL ANTISENSE TRANSCRIPT OF A REPROGRAMMING FACTOR
EP2630241A4 (en) TREATMENT OF ALPHA-L-IDURONIDASE ASSOCIATED DISEASES (IDUA) BY INHIBITION OF THE ENDOGENOUS ANTISENSE TRANSCRIPT OF IDUA
EP2446037A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH THE DOWN SYNDROME GENE BY INHIBITION OF THE NATURAL ANTISENSE TRANSCRIPT TO A DOWN SYNDROME GENE
SI2585596T1 (sl) Zdravljenje bolezni, povezanih z alfa podenoto (scna) napetostnega natrijevega kanala z inhibicijo naravne protismiselne rnk na scna
EP2718439A4 (en) TREATMENT OF FRATAXIN-RELATED DISEASES (FXN) BY INHIBITION OF NATURAL ANTI-SENSE TRANSCRIPTION OF FXN
EP2521785A4 (en) TREATMENT OF ILLNESSES RELATED TO PANCREATIC DEVELOPMENT GENES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPTION TO A PANCREAS DEVELOPMENT GENE
EP2435571A4 (en) TREATMENT OF ANTIVIRAL GENE-RELATED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST AN ANTIVIRAL GEN
EP2519633A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH NUCLEAR RESPIRATOR FACTOR 1 (NRF1) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST NRF1
HK1219111A1 (zh) 通過抑制' -相互作用蛋白的 末端' 的天然反義轉錄物而治療 相關疾病
HK1221914A1 (zh) 通過抑制針對腦衍生神經營養因子 的天然反義轉錄物來治療 相關的疾病
EP2625274A4 (en) TREATMENT OF SIALIDASE-4 (NEU4) -IMBLE DISORDERS BY INHIBITION OF THE NATURAL ANTISENSE TRANSCRIPT AGAINST NEU4
EP2513310A4 (en) TREATMENT OF ILLNESSES ASSOCIATED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR PEPTIDASE LOCATION 1 (MBTPS1) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST MBTPS1
EP2516648A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH HEPATOCYTE GROWTH FACTOR (HGF) BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HGF
EP2370579A4 (en) TREATMENT OF ERYTHROPOIETIN (EPO) RELATED DISEASES BY INHIBITION OF A NATURAL ANTISENSE TRANSCRIPT OF EPO
EP2443238A4 (en) TREATMENT OF PARAOXONASE 1 (PON1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION PRODUCT TO PON1
EP2569432A4 (en) TREATMENT OF PAR4-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION PRODUCT OF PAR4
EP2464731A4 (en) TREATMENT OF ADIPONECTIN-ASSOCIATED DISEASES (ADIPOQ) BY INHIBITION OF NATURAL ANTI-SENSE TRANSCRIPTION PRODUCT OF ADIPONECTIN (ADIPOQ)
EP2643463A4 (en) TREATMENT OF NANOG-ASSOCIATED DISEASES BY INHIBITION OF A NATURAL ANTISENSE TRANSCRIPT OF NANOG